OraSure Technologies Commends New York State Hepatitis C Testing Law

OraSure Technologies Commends New York State Hepatitis C Testing Law

New Law Requires Health Service Providers to Offer a One-Time Hepatitis C Test
to Individuals Born Between 1945 and 1965

BETHLEHEM, Pa., Oct. 23, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) applauds New York State's new hepatitis C (HCV) testing law,
which requires providers in all clinical settings in the state of New York
(except emergency rooms) to offer a one-time HCV test toindividuals born
between 1945 and 1965. Governor Andrew Cuomo signed the bill into law today
and it will take effect as of January 1, 2014.

According to the Centers for Disease Control and Prevention (CDC), HCV is the
most common chronic blood-borne infection in the United States. Up to 75
percent of people with hepatitis C are unaware of their infection. It is
estimated that Baby Boomers (adults born between 1945 and 1965) are five times
more likely to have hepatitis C than other adults. The CDC recommends that all
Baby Boomers, approximately 78.2 million individuals, be tested for hepatitis
C at least once.

"We applaud New York State on its new hepatitis C testing law, and for its
leadership in taking action to fight the hepatitis C epidemic," said Douglas
A. Michels, President and Chief Executive Officer of OraSure Technologies. "As
a result of this new law, we believe more individuals at risk for HCV will get
tested and learn their hepatitis C status. With the use of our OraQuick® Rapid
HCV test, individuals presumed to be infected can be referred immediately for
follow-up care."

The OraQuick® HCV Rapid Antibody Test is the first and only FDA-approved,
CLIA-waived rapid, point-of-care test for the detection of antibodies to the
hepatitis C virus. OraQuick® HCV results are available in 20 minutes, which
can help increase the delivery of test results, allowing early diagnosis and
linkage to care, treatment and prevention services, particularly for those at
risk for hepatitis C.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and
distribution of oral fluid diagnostic and collection devices and other
technologies designed to detect or diagnose critical medical conditions. Its
innovative products include rapid tests for the detection of antibodies to HIV
and HCV at the point of care and testing solutions for detecting various drugs
of abuse. In July 2012, the Company received approval from the U.S. Food and
Drug Administration for the Company's OraQuick® In-Home HIV Test for sale
directly to consumers in the over-the-counter (OTC) market - making it the
first and only rapid OTC HIV test approved in the U.S. In addition, the
Company is a leading provider of oral fluid sample collection, stabilization
and preparation products for molecular diagnostic applications. OraSure's
portfolio of products is sold globally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors, government
agencies, physicians' offices, and commercial and industrial entities. The
Company's products enable healthcare providers to deliver critical information
to patients, empowering them to make decisions to improve and protect their
health.

For more information on OraSure Technologies, please visit www.orasure.com.

CONTACT: Media Contact:
         Jennifer Moritz
         Zer0 to 5ive for OraSure Technologies
         917-748-4006
         jmoritz@0to5.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.